Imrecoxib

Research use only, not for human use.

Imrecoxib is a novel and selective cyclooxygenase 2 (COX-2) inhibitor (IC50: 18 nM).

Imrecoxib is a novel and selective cyclooxygenase 2 (COX-2) inhibitor (IC50: 18 nM). It also inhibits COX1- activity (IC50: 115 nM). Imrecoxib has an anti-inflammatory effect.

Imrecoxib (BAP-909) (0.1-10 μM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells. RT-PCRCell Line:U937 cells Concentration:0.1 μM; 1 μM; 10 μM Incubation Time:24 hours Result:Decreased COX-2 mRNA level.

Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours.Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis. Animal Model:Rat carrageenan-induced edema modelDosage:5 mg/kg, 10 mg/kg, 20 mg/kg Administration:Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection Result:Inhibited the edema response with different doses.Animal Model:Rat adjuvant-induced arthritis (AIA) model Dosage:5 mg/kg, 10 mg/kg, 20 mg/kg Administration:Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days Result:Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg.

BAP-909

Chromatin/Epigenetic

COX

COX-1|COX-2

——

——

395683-14-4

369.48

C21H23NO3S

>98% (HPLC)

DMSO: 90 mg/mL (243.59 mM; Need ultrasonic)

O=C1N(CCC)CC(C2=CC=C(S(=O)(C)=O)C=C2)=C1C3=CC=C(C)C=C3

——

(-20℃)

With Ice Pack

≥ 2 years